TrialThe Lancet. Oncology2016

Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial.

Alexander Drilon et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.